System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Thomas Eigentler is an expert in Oncology at Universitätsklinikum Tübingen (Germany). As of October 2026, ScienceLeadR ranks Thomas Eigentler in the top 1% of experts worldwide for Non-Melanoma Skin Neoplasms, Skin Neoplasms and Melanoma. Thomas Eigentler has authored 438 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 12 of them ongoing. SLR score: 1,874 (community average: 125). How the SLR is computed.

LeadR Profile

Thomas Eigentler Universitätsklinikum Tübingen Germany
1 874 ScienceLeadR Reputation 1874

Unlock

Register Login
Network Map

Oncology

Subspecialties: Dermatology - Public Health - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Charité - University Medicine Berlin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 438

Citations

Citations: 18 742 1st author: 33 Last author: 30 Unique author: 7

Main journals

J Dtsch Dermatol Ges 62
J Clin Oncol 39
Eur J Cancer 28
Ann Oncol 27
J Immunother Cancer 13

Best Journals

J Clin Oncol 18
Ann Oncol 17
Lancet Oncol 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part IV: Palliative Management of Painful Bone Metastases, Pain Relief - and Beyond.
PMID 42675965 — cells, pain, neoplasms, neoplasm metastasis, therapeutics, wounds and injuries, pulse		Cell Physiol Biochem20260
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.
PMID 42579833 — safety, melanoma, therapeutics, medical oncology		J Clin Oncol Top journal20260
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.
PMID 42393046 — registries, biological science disciplines, probability, melanoma, neoplasms, diagnosis, prospective studies		Nat Commun20260
Tildrakizumab resolves multirefractory immune checkpoint inhibitor-induced colitis in metastatic melanoma.
PMID 42203146 — colitis, melanoma, immune checkpoint inhibitors		Clin Res Hepatol Gastroenterol20260
Years of life lost in cutaneous squamous cell carcinoma: analysis of a prospective cohort of 1400 patients.
PMID 42184051 — cells, mortality, carcinoma, squamous cell, life expectancy, sex, risk factors, medical oncology, immunosuppression therapy, cutaneous squamous cell carcinoma		J Cancer Res Clin Oncol20260

Clinical Studies 37

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7

By phase:

Phase 2 17
Phase 3 10
N/A 3
Phase 1 3
Phase 1/Phase 2 2
Phase 2/Phase 3 2

By status:

Completed 12
Recruiting 11
Terminated 5
Active not recruiting 4
Unknown 3
Not yet recruiting 2

By type:

Interventional 35
Observational 2

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 3
multicentric5to9 2
multicentricup10 27

Main Topics

Ongoing Clinical Trials

12 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
L19IL2 L19TNF in patients with cutaneous squamous cell carcinoma
2025-523231-19-00 — cells, carcinoma, squamous cell, therapeutics, carcinoma, cutaneous squamous cell carcinoma		Phase 2Not yet recruiting2026
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma
2023-503652-27-00 — melanoma, rna, messenger		Phase 3Active not recruiting2023
L19IL2 or L19TNF or L19IL2 TNF in patients with basal cell carcinoma (BCC)
2025-523229-16-00 — injections, cells, injections, intralesional, therapeutics, carcinoma, basal cell, carcinoma		Phase 2Recruiting2026
L19IL2 TNF in patients with basal cell carcinoma
2025-523230-77-00 — injections, cells, therapeutics, carcinoma, basal cell, carcinoma		Phase 2Not yet recruiting2026
Clinical Study on High fiber Diet and Short term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition
NCT07680452 — skin, fasting, melanoma, neoplasms, diet, immunotherapy, immune system, therapeutics, bacteria, skin neoplasms, intermittent fasting		N/ARecruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS